Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NE

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T. In order to participate in the conference call, please register at https://bit.ly/3BTJ9Z7. Participants can register via this link up to ten minutes prior to start time. The webcast and presentation will be made ava

- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of platform into autoimmune diseases with TRuC Tregs - TCR2 to host a webcast on Wednesday, October 20 at 8:00a.m. ET CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.

- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall response rate (ORR) 31% in patients infused with gavo-cel following lymphodepletion - Meaningful survival benefit at 11.2 months for patients with refractory mesothelioma - Recommended Phase 2 Dose (RP2D) being refined after identification of the Maximum Tolerated Dose (MTD) - TCR2 to host a conference call on Friday, September 17 at 9:00a.m. ET CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company wi

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio webcast on Friday, September 17, 2021 at 9:00am E.T. to discuss extended data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors. The dataset will be an extension of the oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 17 at 14:20 CEST (8:20am ET) (Presentation #959O) that is part of the official ESMO P

15-12G - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

POS AM - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

POS AM - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

POS AM - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

S-8 POS - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

S-8 POS - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

S-8 POS - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies' complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the w

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2's common stock to one non-executive new hire. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.77, which represents the closing market price

CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2's common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.50, which represents the closing mar

TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumorsFollowing the expected Q2 2023 closing of the all-stock transaction, the combined company's cash runway is expected to extend into 2026 CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (NASDAQ:TCRR) (TCR² or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced fourth quarter and full-year 2022 financial results and provided a corporate update. "Focus and specialization are critical in the cell therapy space. The strategic

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada

CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET. A live webcast of the presentation will be available on the Investors page of the Company's website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation. About TCR² TherapeuticsTCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 9,600 shares of TCR2's common stock to 3 new non-executive employees. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $0.83, which represents the closing market

gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation enhanced programs TC-510 and TC-520 prioritized with TC-510 Phase 1 clinical trial ongoing and first meaningful objective response data expected in 2H 2023Company to be streamlined with approximately 40 percent reduction in workforceExpected cash runway extended into early 2025 due to cost savings CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced its pi

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 24,400 shares of TCR2's common stock to 3 new non-executive employees. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.33, which represents the closing marke

Goldman downgraded TCR2 Therapeutics from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

HC Wainwright & Co. reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $19.00 from $25.00 previously

Piper Sandler resumed coverage of TCR2 Therapeutics with a rating of Overweight and set a new price target of $26.00 from $55.00 previously

SVB Leerink reiterated coverage of TCR2 Therapeutics with a rating of Market Perform and set a new price target of $7.00 from $8.00 previously

SVB Leerink downgraded TCR2 Therapeutics from Outperform to Mkt Perform and set a new price target of $8.00 from $18.00 previously

Truist Securities reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $29.00 from $40.00 previously

HC Wainwright & Co. reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $25.00 from $37.00 previously

Wedbush downgraded TCR2 Therapeutics from Outperform to Neutral and set a new price target of $11.00 from $45.00 previously

SVB Leerink reiterated coverage of TCR2 Therapeutics with a rating of Outperform and set a new price target of $31.00 from $34.00 previously

Goldman Sachs initiated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $30.00

The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Sensus Healthcare The Trade: Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Samuel O'Rear acquired a total 20,000 shares an average price of $2.99. To acquire these shares, it cost around $59.85 thousand. The company’s President and General Counsel also bought

TCR2 Therapeutics (NASDAQ:TCRR) reported its Q1 earnings results on Thursday, May 11, 2023 at 06:30 AM. Here's what investors need to know about the announcement. Earnings TCR2 Therapeutics missed estimated earnings by 51.47%, reporting an EPS of $-1.03 versus an estimate of $-0.68. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.77 which was followed by a 5.63% increase in the share price the next day. Listen to the earnings announcement yourself by clicking here. To track all earnings releases for TCR2 Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content eng

TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.03) per share. This is a 35.53 percent decrease over losses of $(0.76) per share from the same period last year.

The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Ribbon Communications The Trade: Ribbon Communications Inc. (NASDAQ:RBBN) Preseident and CEO William Bruce McClelland acquired a total 10,000 shares an average price of $2.60. To acquire these shares, it cost around $26 thousand. The company’s EVP and CFO a

Upgrades Argus Research upgraded the previous rating for Cracker Barrel Old Country Store Inc (NASDAQ:CBRL) from Hold to Buy. For the second quarter, Cracker Barrel Old had an EPS of $1.48, compared to year-ago quarter EPS of $1.71. At the moment, the stock has a 52-week-high of $126.26 and a 52-week-low of $81.92. Cracker Barrel Old closed at $112.41 at the end of the last trading period. JP Morgan upgraded the previous rating for KB Home (NYSE:KBH) from Underweight to Neutral. KB Home earned $1.45 in the first quarter, compared to $1.47 in the year-ago quarter. The current stock performance of KB Home shows a 52-week-high of $40.92 and a 52-week-low of $24.79. Moreover, at the end of th

Mizuho analyst Mara Goldstein downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral and lowers the price target from $20 to $1.72.

EF Hutton analyst Tony Butler reiterates TCR2 Therapeutics (NASDAQ:TCRR) with a Hold and maintains $2 price target.

TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.56) per share. This is a 116.67 percent decrease over losses of $(0.72) per share from the same period last year.

Jefferies downgraded its rating of TCR2 Therapeutics (NASDAQ:TCRR) to Underperform with a price target of $3.00, changing its price target from $18.00 to $3.00. Shares of TCR2 Therapeutics are trading up 1.94% over the last 24 hours, at $1.58 per share. A move to $3.00 would account for a 89.87% increase from the current share price. About TCR2 Therapeutics TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically rec

Upgrades For HNI Corp (NYSE:HNI), Sidoti & Co. upgraded the previous rating of Neutral to Buy. For the fourth quarter, HNI had an EPS of $0.63, compared to year-ago quarter EPS of $0.43. At the moment, the stock has a 52-week-high of $39.54 and a 52-week-low of $24.61. HNI closed at $26.82 at the end of the last trading period. According to Credit Suisse, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Neutral to Outperform. In the fourth quarter, Nuvei showed an EPS of $0.47, compared to $0.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $79.13 and a 52-week-low of $23.71. Nuvei closed at $36.41 at the end of the last trading period. Accordi